


TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) 371 CONCERNING A FILING UNDER 35 U.S.C.		ATTORNEY'S DOCKET NUMBER TIP0043 USPCT
		U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 107524451
INTERNATIONAL APPLICATION NO. PCT/EP2003/50379	INTERNATIONAL FILING DATE 14 AUG 2003	PRIORITY DATE CLAIMED 14 AUG 2002
TITLE OF INVENTION BROADSPECTRUM SUBSTITUTED OXINDOLE SULFONAMIDE HIV PROTEASE INHIBITORS		
APPLICANT(S) FOR DO/EO/US: Abdellah TAHRI, Piet Tom Bert Paul WIGERINCK		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none">1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below4. <input type="checkbox"/> The US has been elected (Article 31).5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))<ol style="list-style-type: none">a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau), as well as the Published Application No. WO 2004/016619 A1.b. <input type="checkbox"/> has been communicated by the International Bureau.c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).<ol style="list-style-type: none">a. <input type="checkbox"/> is attached heretob. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))<ol style="list-style-type: none">a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).b. <input type="checkbox"/> have been communicated by the International Bureau.c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.d. <input checked="" type="checkbox"/> have not been made and will not be made.8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)) has been filed in the PCT Request (Rule 4.17 (iv)).10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <p>Items 11 to 20 below concern document(s) or information included:</p> <ol style="list-style-type: none">11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.13. <input checked="" type="checkbox"/> A preliminary amendment.14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.15. <input type="checkbox"/> A substitute specification.16. <input checked="" type="checkbox"/> A power of attorney and/or change of address letter.17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.18. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4).19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).20. <input checked="" type="checkbox"/> Other items or information: A PCT Notification of the Recording of Change, Certificate Under 37 CFR 3.73(b), Return receipt Postcard & Express Mail Certificate		

This collection of information is required by 37 CFR 1.414 AND 1.491-1.492. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. 10/524451		INTERNATIONAL APPLICATION NO. PCT/EP2003/50379		ATTORNEY'S DOCKET NUMBER TIP0043 USPCT	
21. <input checked="" type="checkbox"/> The following fees are submitted: <input checked="" type="checkbox"/> a) Basic national fee \$300.00 <input checked="" type="checkbox"/> b) Examination fee..... \$200.00 <input checked="" type="checkbox"/> c) Search fee..... \$500.00 TOTAL OF ABOVE CALCULATIONS = \$ 1000.00				Applicant use	Office use only
				\$	
				\$	
				\$	
				\$ 1000.00	
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE		
52 - 100 =	0 /50 =	0	x \$250.00	\$	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	17 -20	0	x \$50.00		
Independent claims	2 - 3	0	x 200.00		
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$300.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$1000.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	
SUBTOTAL =				\$1000.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).					
TOTAL NATIONAL FEE =				\$	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+	\$
TOTAL FEES ENCLOSED =				\$1000.00	
Amount to be refunded:					\$
Amount to be charged:					\$
a. <input type="checkbox"/> A check in the amount of \$_____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>10-0750/TIP0043USPPCT/AGK</u> in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>10-0750/TIP0043USPCT/AGK</u> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit Card information should not be included on this form. Provide credit card information and authorization on PTO-2038. NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: Philip S. Johnson, Esq. Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 USA			<div style="text-align: center;">  Signature </div> Name: Alana G. Kriegsman Reg. No. 41,747 Attorney for Applicants Dated: February 10, 2005		

10/524451

Express Mail Label No. EV 488941470US

Docket No. TIP0043 US PCT

BT01 Rec'd PCT/PT 10 FEB 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: TAHRI, Abdellah; WIGERINCK, Piet Tom Bert Paul

For: BROADSPECTRUM SUBSTITUTED OXINDOLE SULFONAMIDE HIV PROTEASE
INHIBITORSExpress Mail Certificate

"Express Mail" mailing number: EV 488941470 US

Date of Deposit: February 10, 2005

I hereby certify that this entry into the National Phase pursuant to 35 USC 371 contains
complete application:

<input checked="" type="checkbox"/>	Express Mail Certificate	(1 page)
<input checked="" type="checkbox"/>	Return Receipt Postcard	(1 page)
<input checked="" type="checkbox"/>	PCT FORM 1390 Transmittal	(2 pages & copy)
<input checked="" type="checkbox"/>	Copy of International Application as filed	(52 pages)
<input checked="" type="checkbox"/>	Published Applic. No. WO 2004/016619 A1	(27 pages/double sided)
<input checked="" type="checkbox"/>	Preliminary Amendment	(12 pages)
<input checked="" type="checkbox"/>	PCT Notification of the Recording	(2 pages)
<input checked="" type="checkbox"/>	Power of Attorney or Authorization of Agent	(1 page)
<input checked="" type="checkbox"/>	Certificate Under 37 CFR 3.73 (b)	(2 pages)
<input checked="" type="checkbox"/>	Information Disclosure Statement	(3 pages)
<input checked="" type="checkbox"/>	Form 1449 (with all References)	(2 pages)
<input checked="" type="checkbox"/>	International Search Report dated 11/26/3003 for PCT/EP2003/50379	(2 pages)
<input checked="" type="checkbox"/>	Submission Under MPEP 609 D	(1 page)

is being deposited with the United States Postal Service "Express Mail Post Office to
Addressee; service under 37 CFR 1.10 on the date indicated above is addressed to the Mail
Stop: PCT, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450..

Margaret Turner

(Typed or printed name of person mailing paper or fee)

Margaret Turner

(Signature of person mailing paper or fee)

TIP-043-USA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Tibotec Pharmaceuticals Ltd.
Serial No.: Art Unit:
Filed : Examiner:
For : BROADSPECTRUM SUBSTITUTED OXINDOLE SULFONAMIDE HIV
PROTEASE INHIBITORS

Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE UNDER 37 CFR 3.73(b)

Tibotec Pharmaceuticals Ltd., a Corporation, certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of either:

A. ☒ An assignment from the inventor(s) of the patent application identified above. The assignments were recorded in the Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), or the patent application identified above, to the current assignee as shown below:

1. From:
To:
The document was recorded in the Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached.

2. From:
To:
The document was recorded in the Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached.

3. From:
To:

10/524451

BT01 Rec'd PCT/PTC 10 FEB 2005

The document was recorded in the Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned (whose title is supplied below) is empowered to sign this certificate on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

24 January 2005
Date

Frank Daelemans
Signature

Frank Daelemans
Typed or Printed Name

Proxy Holder
Title